创新药企业扭亏节点或加速到来，港股通医疗ETF工银(159167)将于2月12日在深交所上市交易

Group 1 - The core viewpoint of the news highlights the positive performance of innovative pharmaceutical companies, with many showing improved operations and reduced losses or even turning profitable in their 2025 reports, signaling a favorable outlook for the sector [1] - The ICBC Credit Suisse CSI Hong Kong Stock Connect Medical Theme ETF (code: 159167) is set to be listed on the Shenzhen Stock Exchange on February 12, 2026, aiming to track the CSI Hong Kong Stock Connect Medical Theme Index, which covers key sectors in healthcare innovation [1][2] - The CSI Hong Kong Stock Connect Medical Theme Index currently has a price-to-earnings ratio (TTM) of 32.85, which is at the 48.16% percentile since its inception, indicating that the index may not be overvalued and could still present attractive investment opportunities [1] Group 2 - In 2025, the number of new drug License-out transactions in China reached 158, with a total scale of $135.7 billion, marking a ten-year high, which significantly boosts short-term performance expectations and promotes the international development of domestic new drugs [2] - The CXO, innovative drugs, and high-value consumables sectors have shown significant growth in 2025, driven by the ongoing favorable conditions in the global innovative pharmaceutical industry and the recovery of domestic surgical demand [2] - The ICBC Credit Suisse Medical ETF (159167) aims to leverage the trends in the Hong Kong medical sector to provide beta returns for investors, capitalizing on investment opportunities within the sector [2]